Head-to-head evidence
Ezogabine vs Opakalim
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: Kv7 potassium channel · full Epilepsy pipeline
Ezogabine · Potiga
Marketed by GlaxoSmithKline
NCT00235755 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial with approximately 180 participants per group. Its primary clinical seizure-frequency endpoint was statistically significant for both retigabine doses versus placebo, with the higher dose showing the larger reduction; the prespecified responder endpoint also significantly favored both doses.
Opakalim
Developed by Biohaven
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT06443463 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ezogabine's landscape · Opakalim's landscape